Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. Ratner ES, et al. Among authors: pecorelli s. Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5. Oncogene. 2012. PMID: 22139083 Free PMC article.
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Roque DM, et al. Among authors: pecorelli s. Am J Obstet Gynecol. 2013 Jul;209(1):62.e1-9. doi: 10.1016/j.ajog.2013.04.017. Epub 2013 Apr 10. Am J Obstet Gynecol. 2013. PMID: 23583215
Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Bellone S, et al. Among authors: pecorelli s. Int J Gynecol Cancer. 2009 Jul;19(5):860-6. doi: 10.1111/IGC.0b013e3181a8331f. Int J Gynecol Cancer. 2009. PMID: 19574774
Serum amyloid A: a novel biomarker for endometrial cancer.
Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Cocco E, et al. Among authors: pecorelli s. Cancer. 2010 Feb 15;116(4):843-51. doi: 10.1002/cncr.24838. Cancer. 2010. PMID: 20041483 Free PMC article.
High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
Richter CE, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Richter CE, et al. Among authors: pecorelli s. Am J Obstet Gynecol. 2010 Dec;203(6):582.e1-7. doi: 10.1016/j.ajog.2010.07.041. Epub 2010 Sep 25. Am J Obstet Gynecol. 2010. PMID: 20870202 Free PMC article.
High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.
Varughese J, Cocco E, Bellone S, Bellone M, Todeschini P, Carrara L, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Varughese J, et al. Among authors: pecorelli s. Gynecol Oncol. 2011 Jul;122(1):171-7. doi: 10.1016/j.ygyno.2011.03.002. Epub 2011 Mar 30. Gynecol Oncol. 2011. PMID: 21453957 Free PMC article.
Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody.
Bellone M, Cocco E, Varughese J, Bellone S, Todeschini P, El-Sahwi K, Carrara L, Guzzo F, Schwartz PE, Rutherford TJ, Pecorelli S, Marshall DJ, Santin AD. Bellone M, et al. Among authors: pecorelli s. Int J Gynecol Cancer. 2011 Aug;21(6):1084-90. doi: 10.1097/IGC.0b013e3182187324. Int J Gynecol Cancer. 2011. PMID: 21633302 Free PMC article.
Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Siegel E, Varughese J, Arin-Silasi D, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE, Santin AD. Casagrande F, et al. Among authors: pecorelli s. Cancer. 2011 Dec 15;117(24):5519-28. doi: 10.1002/cncr.26215. Epub 2011 Jun 20. Cancer. 2011. PMID: 21692061 Free PMC article.
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.
Cocco E, Varughese J, Buza N, Bellone S, Lin KY, Bellone M, Todeschini P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Carrara L, Tassi R, Pecorelli S, Lockwood CJ, Santin AD. Cocco E, et al. Among authors: pecorelli s. Clin Exp Metastasis. 2011 Oct;28(7):689-700. doi: 10.1007/s10585-011-9401-0. Epub 2011 Jul 2. Clin Exp Metastasis. 2011. PMID: 21725665 Free PMC article.
Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.
Varughese J, Cocco E, Bellone S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Santin AD. Varughese J, et al. Among authors: pecorelli s. Am J Obstet Gynecol. 2011 Dec;205(6):567.e1-7. doi: 10.1016/j.ajog.2011.06.093. Epub 2011 Jul 13. Am J Obstet Gynecol. 2011. PMID: 21889762 Free PMC article.
310 results